[go: up one dir, main page]

DE602004012424D1 - Homogene herstellungen von il-29 - Google Patents

Homogene herstellungen von il-29

Info

Publication number
DE602004012424D1
DE602004012424D1 DE602004012424T DE602004012424T DE602004012424D1 DE 602004012424 D1 DE602004012424 D1 DE 602004012424D1 DE 602004012424 T DE602004012424 T DE 602004012424T DE 602004012424 T DE602004012424 T DE 602004012424T DE 602004012424 D1 DE602004012424 D1 DE 602004012424D1
Authority
DE
Germany
Prior art keywords
amino acid
seq
cysteine
acid residues
correspond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004012424T
Other languages
English (en)
Other versions
DE602004012424T2 (de
Inventor
Lowell J Brady
Kevin M Klucher
Chung Chan
Dennis L Dong
Hong Y Liu
Paul O Sheppard
Thomas R Bukowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zymogenetics Inc
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Publication of DE602004012424D1 publication Critical patent/DE602004012424D1/de
Application granted granted Critical
Publication of DE602004012424T2 publication Critical patent/DE602004012424T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE602004012424T 2003-08-07 2004-08-09 Homogene herstellungen von il-29 Expired - Lifetime DE602004012424T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US49319403P 2003-08-07 2003-08-07
US493194P 2003-08-07
US55184104P 2004-03-10 2004-03-10
US551841P 2004-03-10
US55914204P 2004-04-02 2004-04-02
US559142P 2004-04-02
PCT/US2004/025864 WO2005023862A2 (en) 2003-08-07 2004-08-09 Homogeneous preparations of il-28 and il-29

Publications (2)

Publication Number Publication Date
DE602004012424D1 true DE602004012424D1 (de) 2008-04-24
DE602004012424T2 DE602004012424T2 (de) 2009-04-30

Family

ID=34279787

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012424T Expired - Lifetime DE602004012424T2 (de) 2003-08-07 2004-08-09 Homogene herstellungen von il-29

Country Status (15)

Country Link
US (38) US7157559B2 (de)
EP (4) EP1927600A1 (de)
JP (2) JP4808157B2 (de)
CN (1) CN1910200A (de)
AT (1) ATE388963T1 (de)
AU (1) AU2004270652B2 (de)
CA (1) CA2534907C (de)
CY (1) CY1114030T1 (de)
DE (1) DE602004012424T2 (de)
DK (2) DK2251353T3 (de)
ES (2) ES2405209T3 (de)
IL (1) IL210381A0 (de)
PL (1) PL2251353T3 (de)
PT (1) PT2251353E (de)
WO (1) WO2005023862A2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP2132984A3 (de) 2000-06-30 2010-11-03 ZymoGenetics, L.L.C. Interferonähnliches Protein ZCYTO21
US7910313B2 (en) * 2001-04-20 2011-03-22 Zymogenetics, Inc. Cytokine protein family
US7038032B2 (en) 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
WO2004037995A2 (en) * 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
ATE479763T1 (de) 2003-04-29 2010-09-15 Avi Biopharma Inc Zusammensetzungen zur verbesserung der antisense- wirksamkeit und des transports von nukleinsäureanalog in zellen
CN1910200A (zh) 2003-08-07 2007-02-07 津莫吉尼蒂克斯公司 Il－28和il－29的均一化制剂
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
AU2005231476B2 (en) * 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
CN101829318B (zh) * 2004-07-29 2012-07-04 津莫吉尼蒂克斯有限责任公司 Il-28和il-29治疗癌症和自身免疫性疾病的用途
EP1848737B1 (de) * 2005-01-28 2016-05-18 ZymoGenetics, Inc. Homogene präparate von il-31
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
JP4987001B2 (ja) * 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
CA2616122A1 (en) * 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
PL1931704T3 (pl) 2005-10-04 2011-06-30 Zymogenetics L L C Wytwarzanie i oczyszczanie IL-29
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
MX2010003055A (es) * 2007-09-20 2010-06-30 Commw Scient Ind Res Org Nuevas citocinas aviares y secuencias geneticas que las codifican.
US8354125B2 (en) 2007-10-27 2013-01-15 Grant Gallagher Ex-vivo treatment of peripheral blood leukocytes with IFN-λ
ES2570853T3 (es) 2007-12-07 2016-05-20 Zymogenetics Inc Moléculas de anticuerpo humanizadas específicas para IL-31
CN102016023A (zh) 2008-04-04 2011-04-13 宾夕法尼亚州立大学托管会 使用il-28和组合物的疫苗和免疫治疗及其使用方法
CA2727026A1 (en) * 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c
JP2012500855A (ja) * 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよび感染性疾患を処置するための方法
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
US8363580B2 (en) * 2009-03-31 2013-01-29 Rosemount Inc. Disparate radios in a wireless mesh network
EP2362332A1 (de) 2010-02-26 2011-08-31 Seremfor, S.L.U. Verfahren und System zum automatischen Kontrollieren von persönlicher Schutzausrüstung, Systeme und technische Arbeitsanweisungen im Hinblick auf Laborgefahrenverhütung
EP3023496B1 (de) * 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
WO2012065755A1 (en) * 2010-11-19 2012-05-24 Bavarian Nordic A/S Production of ifn-lambda by b cells
CN102584979B (zh) * 2011-01-18 2015-10-14 北京凯因科技股份有限公司 PEG化干扰素λ
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
FR2975185A1 (fr) * 2011-05-12 2012-11-16 Univ Claude Bernard Lyon Procede de determination in vitro de la presence d'une sclerose en plaques
WO2013024156A2 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of anti-hcv-entry factor antibodies and interferons for the treatment and the prevention of hcv infection
WO2013024158A1 (en) 2011-08-17 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations of protein kinase inhibitors and interferons or of protein kinase inhibitors and direct acting antivirals for the treatment and the prevention of hcv infection
WO2013029062A1 (en) * 2011-08-25 2013-02-28 Nanogen Pharmaceutical Biotechnology Co., Ltd Peginterferon lambda 1 conjugates, processes for their preparation, pharmaceutical compositions containing these conjugates and processes for making the same
CN102559737A (zh) * 2011-12-13 2012-07-11 江南大学 一种人白细胞介素29的变异体及其制备方法
WO2014033266A1 (en) 2012-08-31 2014-03-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-sr-bi antibodies for the inhibition of hepatitis c virus infection
US10550171B2 (en) * 2012-11-21 2020-02-04 The Governors Of The University Of Alberta Immunomodulatory peptides and methods of use thereof
US9464321B2 (en) * 2013-03-15 2016-10-11 Medical Diagnostic Laboratories, Llc Methods and reagents that specifically detect, distinguish and quantify IFN-λ2 mRNA from IFN-λ3 mRNA in humans
WO2015103749A1 (en) * 2014-01-08 2015-07-16 Prosit Sole Biotechnology (Beijing) Co. Ltd Fusion polypeptides and methods of use
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
CN104672318A (zh) * 2014-12-17 2015-06-03 江南大学 一种肽链第43位赖氨酸定点突变为亮氨酸的人白介素-29变异体
CN107530338B (zh) 2015-04-21 2020-12-01 艾格尔峰生物制药有限公司 包含洛那法尼和利托那韦的药物组合物
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
CN105037523B (zh) * 2015-06-25 2019-02-19 北京三元基因药业股份有限公司 干扰素突变体及其聚乙二醇衍生物
HUE054191T2 (hu) 2015-11-04 2021-08-30 Eiger Biopharmaceuticals Inc A hepatitis delta vírusfertõzés kezelése
DK3393496T5 (da) * 2015-12-23 2024-09-16 Univ Johns Hopkins Long-acting glp-1r agonist as a therapy of neurological and neurodegenerative conditions
JP7674628B2 (ja) 2016-02-19 2025-05-12 イーアイティー・ファーマ・インコーポレイテッド インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置
CN106047806B (zh) * 2016-08-19 2019-07-16 上海逍鹏生物科技有限公司 一种适用于高密度细胞培养体系的外周血细胞培养基
MX2019003744A (es) * 2016-09-30 2019-10-30 Univ Leland Stanford Junior Interferones de variante tipo iii y sintecinas.
EP3375452B1 (de) * 2017-03-16 2025-01-08 Evangelos Andreakos Verwendung von lambda-interferonen bei der behandlung einer mit fettleibigkeit in zusammenhang stehenden störung, von atherosklerose oder einer gerinnungsstörung
CN107043740A (zh) * 2017-05-10 2017-08-15 浙江美保龙生物技术有限公司 一种mdbk细胞培养液及其制备方法、使用方法
CN107630086B (zh) * 2017-11-13 2020-11-03 吉林大学 一种与hbv感染相关的snp分子标记及其应用
CN108070647B (zh) * 2017-12-25 2021-06-01 吉林大学 与hbv感染相关的基因单体型及其应用
CN108570459B (zh) * 2018-04-10 2022-10-04 南京农业大学 一种高效发酵生产重组细菌漆酶的方法
AU2021217681A1 (en) * 2020-02-06 2022-08-18 Eiger Innotherapeutics, Inc. Treatment of coronavirus infection with interferon lambda
US20210285000A1 (en) 2020-03-05 2021-09-16 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
CA3185614A1 (en) 2020-06-22 2021-12-30 Janssen Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis d virus infection
CN115385998B (zh) * 2021-04-13 2025-08-05 杭州先为达生物科技股份有限公司 稳定的iii型干扰素蛋白及其融合蛋白
CN116219078B (zh) * 2023-05-08 2023-07-11 上海惠盾因泰生物科技有限公司 一种il-29生物学活性测定方法

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US485332A (en) * 1892-11-01 Wagon-brake
DK170236B1 (da) 1980-01-08 1995-07-10 Biogen Inc Rekombinante DNA-molekyler, fremgangsmåde til fremstilling af et polypeptid af IFN-alfa typen og fremgangsmåde til udvælgelse af DNA-sekvenser, der koder for polypeptider af IFN-alfa typen
IE54046B1 (en) 1981-08-25 1989-05-24 Celltech Ltd Expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4853332A (en) * 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
EP0154316B1 (de) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemisch modifizierte Lymphokine und Verfahren zu ihrer Herstellung
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
CA1280080C (en) 1984-12-06 1991-02-12 Jacques Oberto Promoters for the expression of foreign genes in yeast, plasmids comprising them, and uses thereof for the production of polypeptides
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) * 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5750375A (en) 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
CA2144651A1 (en) 1992-09-14 1994-03-31 Timothy J. Miller Immortalized cells and uses therefor
CA2183266A1 (en) 1994-02-14 1995-08-17 Richard D. Holly Hematopoietic protein and materials and methods for making it
US5738846A (en) 1994-11-10 1998-04-14 Enzon, Inc. Interferon polymer conjugates and process for preparing the same
US5641655A (en) 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
US6001597A (en) 1995-11-09 1999-12-14 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
CA2237120C (en) 1995-11-09 2005-03-01 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in pichia methanolica
US5955349A (en) 1996-08-26 1999-09-21 Zymogenetics, Inc. Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5736383A (en) 1996-08-26 1998-04-07 Zymogenetics, Inc. Preparation of Pichia methanolica auxotrophic mutants
US5854039A (en) 1996-07-17 1998-12-29 Zymogenetics, Inc. Transformation of pichia methanolica
US5985614A (en) 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
WO2000055324A1 (en) 1999-03-18 2000-09-21 Zymogenetics, Inc. Murine interferon-alpha named also zcyto13
US6924270B2 (en) * 2000-04-20 2005-08-02 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6376585B1 (en) 2000-06-26 2002-04-23 Apex Advanced Technologies, Llc Binder system and method for particulate material with debind rate control additive
EP2132984A3 (de) * 2000-06-30 2010-11-03 ZymoGenetics, L.L.C. Interferonähnliches Protein ZCYTO21
US6822082B2 (en) * 2000-06-30 2004-11-23 Zymogenetics, Inc. Polynucleotides for mammalian secreted protein, Z1055G2P
MXPA03002049A (es) 2000-09-08 2003-07-24 Schering Corp Genes de mamiferos: reactivos y metodos relacionados.
ATE445701T1 (de) 2000-11-28 2009-10-15 Zymogenetics L L C Zytokine rezeptor zcytor19
JP2002308030A (ja) * 2001-04-16 2002-10-23 Yazaki Corp 車両用周辺監視装置
US7038032B2 (en) * 2001-04-20 2006-05-02 Zymogenetics, Inc. Cytokine protein family
CA2441958C (en) * 2001-04-20 2012-01-17 Zymogenetics, Inc. Il-28 polypeptides and polynucleotids
PL373008A1 (en) 2001-05-10 2005-08-08 Immunex Corporation Cytokine polypeptides
TW200300170A (en) 2001-11-09 2003-05-16 Wyeth Corp Type 2 cytokine receptor and nucleic acids encoding same
AU2003215136A1 (en) 2002-02-08 2003-09-02 University Of Medicine And Dentistry Of New Jersey Ifn-a/b-independent mechanism of antiviral protection
BR0309401A (pt) 2002-04-19 2007-02-21 Zymogenetics Inc polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
WO2004037995A2 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
WO2004077898A2 (en) * 2003-02-26 2004-09-10 Wavezero Inc. Methods and devices for connecting and grounding an emi shield to a printed circuit board
CN1910200A (zh) 2003-08-07 2007-02-07 津莫吉尼蒂克斯公司 Il－28和il－29的均一化制剂
US7208541B2 (en) * 2003-08-22 2007-04-24 National Starch And Chemical Investment Holding Corporation Hot melt adhesive
AU2005231476B2 (en) * 2004-04-02 2011-09-01 Zymogenetics, Inc. Il-28 and il-29 cysteine mutants for treating viral infection
JP4468734B2 (ja) * 2004-04-27 2010-05-26 オリンパス株式会社 映像信号処理装置と映像信号処理プログラム
CN101829318B (zh) 2004-07-29 2012-07-04 津莫吉尼蒂克斯有限责任公司 Il-28和il-29治疗癌症和自身免疫性疾病的用途
CN1305902C (zh) 2004-11-25 2007-03-21 汕头大学医学院 一种人白细胞介素29的生产方法及重组il－29工程菌
JP4987001B2 (ja) 2005-07-20 2012-07-25 ザイモジェネティクス リミテッド ライアビリティ カンパニー 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法
CA2616122A1 (en) 2005-07-20 2007-01-25 Zymogenetics, Inc. Il28 and il29 truncated cysteine mutants and antiviral methods of using same
DE102005000107B4 (de) * 2005-08-25 2014-03-13 Hilti Aktiengesellschaft Pneumatisch betriebenes Setzgerät
PL1931704T3 (pl) 2005-10-04 2011-06-30 Zymogenetics L L C Wytwarzanie i oczyszczanie IL-29
CA2727026A1 (en) 2008-06-05 2009-12-10 Zymogenetics, Llc Use of pegylated type iii interferons for the treatment of hepatitis c

Also Published As

Publication number Publication date
US20080279816A1 (en) 2008-11-13
US20070043210A1 (en) 2007-02-22
US7588919B2 (en) 2009-09-15
US7608428B2 (en) 2009-10-27
US8343476B2 (en) 2013-01-01
US20070055052A1 (en) 2007-03-08
DK2251353T3 (da) 2013-06-03
EP1668031B1 (de) 2008-03-12
HK1150618A1 (en) 2012-01-06
US20140178333A1 (en) 2014-06-26
US20070055053A1 (en) 2007-03-08
US20070055051A1 (en) 2007-03-08
US20070059313A1 (en) 2007-03-15
US7629149B2 (en) 2009-12-08
US20070066810A1 (en) 2007-03-22
US20070055054A1 (en) 2007-03-08
US20070048277A1 (en) 2007-03-01
US20070054375A1 (en) 2007-03-08
JP4808157B2 (ja) 2011-11-02
US20070065406A1 (en) 2007-03-22
WO2005023862A9 (en) 2006-06-08
DK1668031T3 (da) 2008-06-30
CY1114030T1 (el) 2016-07-27
US20070042471A1 (en) 2007-02-22
US7662589B2 (en) 2010-02-16
EP2251353B1 (de) 2013-03-06
US7495077B2 (en) 2009-02-24
ES2303132T3 (es) 2008-08-01
US20070048275A1 (en) 2007-03-01
WO2005023862A2 (en) 2005-03-17
EP2251352A1 (de) 2010-11-17
US20070154446A1 (en) 2007-07-05
US7582450B2 (en) 2009-09-01
US7514536B2 (en) 2009-04-07
US7629148B2 (en) 2009-12-08
US20070054374A1 (en) 2007-03-08
CN1910200A (zh) 2007-02-07
US20170209542A1 (en) 2017-07-27
US20070048274A1 (en) 2007-03-01
US20120004161A1 (en) 2012-01-05
US7157559B2 (en) 2007-01-02
ES2405209T3 (es) 2013-05-30
US20070048843A1 (en) 2007-03-01
PL2251353T3 (pl) 2013-08-30
US7468423B2 (en) 2008-12-23
EP2251353A1 (de) 2010-11-17
US20070053875A1 (en) 2007-03-08
US20070059804A1 (en) 2007-03-15
US7662590B2 (en) 2010-02-16
US7544779B2 (en) 2009-06-09
US7595174B2 (en) 2009-09-29
US20070049737A1 (en) 2007-03-01
US8734776B2 (en) 2014-05-27
AU2004270652B2 (en) 2010-06-03
US20070172923A1 (en) 2007-07-26
AU2004270652A1 (en) 2005-03-17
US20070073044A1 (en) 2007-03-29
US20070054377A1 (en) 2007-03-08
US7588918B2 (en) 2009-09-15
US7495079B2 (en) 2009-02-24
US20050037012A1 (en) 2005-02-17
EP1668031A2 (de) 2006-06-14
US7727518B2 (en) 2010-06-01
PT2251353E (pt) 2013-05-07
US20130089517A1 (en) 2013-04-11
US20070117967A1 (en) 2007-05-24
US7517961B2 (en) 2009-04-14
US7608427B2 (en) 2009-10-27
US20070048844A1 (en) 2007-03-01
US9499598B2 (en) 2016-11-22
US20100104531A1 (en) 2010-04-29
US7485702B2 (en) 2009-02-03
US20070048276A1 (en) 2007-03-01
ATE388963T1 (de) 2008-03-15
US7495078B2 (en) 2009-02-24
DE602004012424T2 (de) 2009-04-30
US20070054376A1 (en) 2007-03-08
US20070042469A1 (en) 2007-02-22
US7479542B2 (en) 2009-01-20
WO2005023862A3 (en) 2005-06-16
EP1927600A1 (de) 2008-06-04
CA2534907C (en) 2014-04-29
JP2011200252A (ja) 2011-10-13
CA2534907A1 (en) 2005-03-17
US20070041936A1 (en) 2007-02-22
US7485701B2 (en) 2009-02-03
JP2007528719A (ja) 2007-10-18
US20070166282A1 (en) 2007-07-19
US7638305B2 (en) 2009-12-29
IL210381A0 (en) 2011-03-31
US20070041975A1 (en) 2007-02-22
US20070042470A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
DE602004012424D1 (de) Homogene herstellungen von il-29
DE69839812D1 (de) Analoge des menschlichen interferon-alpha mit niedriger toxizität
ATE404670T1 (de) Allelische variante des interferon-ähnlichen proteins zcyto21
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
WO1995025749A3 (en) Eating suppressant peptides
MX9200709A (es) Activacion mejorada de proteinas recombinadas. activacion mejorada de proteinas recombinadas.
ATE482272T1 (de) Zytokinproteinfamilie
DK0592566T3 (da) IL-6-muteiner med reduceret cysteinantal
DE59108947D1 (de) Neues menschliches, rekombinantes interferon gamma
TW200722104A (en) Low-toxicity, long-circulating human interferon-α analogs
DE60329115D1 (de) Tumorantigenprotein und dessen verwendung
AU637589B2 (en) Ancrod proteins, their production and use
DE60138885D1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
ATE347899T1 (de) Interferon nachahmende peptide und rekombinante proteine
EP1221964A4 (de) Antigene modifikation von polypeptiden
MX9702475A (es) Analogos del factor de crecimiento acido de fibroblasto que tienen estabilidad y acticidad biologica mejoradas.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition